Mesenchymal Cell News Volume 11.06 | Feb 19 2019

TOP STORY

Engineered MSC/Nanomedicine Spheroid as an Active Drug Delivery Platform for Combinational Glioblastoma Therapy

Spheroid formulation enhanced MSC’s tumor tropism and facilitated loading of different types of therapeutic payloads. The system acted as an active drug delivery platform seeking and specifically targeting glioblastoma cells. It enabled effective delivery of combinational protein and chemotherapeutic drugs by engineered MSC and nanocomposite, respectively. [Nano Lett] Abstract

(Ranked by impact factor of the journal)

IN VITRO

Enhanced Osteogenic Differentiation of Human Bone-Derived Mesenchymal Stem Cells in 3-Dimensional Printed Porous Titanium Scaffolds by Static Magnetic Field through Up-Regulating Smad4

Investigators showed that static magnetic field (SMF) promoted osteogenic differentiation of human bone-derived MSCs in vitro. The osteogenic effect might be associated with bone morphogenetic protein-Smad1/5/8-signaling pathway and increased transport of phosphorylated Smad1/5/8 and phosphorylated Smad2/3 to the nucleus by up-regulating Smad4 under SMF conditions. [FASEB J] Abstract

Autofluorescence Is a Reliable In Vitro Marker of Cellular Senescence in Human Mesenchymal Stromal Cells

Scientists correlated cell autofluorescence to senescence using senescence-associated beta-galactosidase assay with chromogenic and fluorescent substrates, gene expression of senescence markers and telomere length. Autofluorescence was further correlated to MSC differentiation assays, MSC stemness markers and cytokine secretion. [Sci Rep] Full Article

Metabolism as an Early Predictor of DPSCs Aging

Through RNA seq and qPCR analysis the authors identified homeobox protein, Barx1, as a marker for dental pulp stem cells (DPSCs). Furthermore, using high throughput transcriptomic and proteomic analysis they identified markers for DPSC populations with accelerated replicative senescence. [Sci Rep] Full Article

Exosomes from Glioma Cells Induce a Tumor-Like Phenotype in Mesenchymal Stem Cells by Activating Glycolysis

The migration and invasion of human bone marrow MSCs (hBMSCs) were evaluated with a Transwell assay. A proteomics and bioinformatics approach, together with Western blotting and reverse transcriptase-polymerase chain reaction, was used to investigate the effect of U251 cell-derived exosomes on the proteome of hBMSCs. [Stem Cell Res Ther] Full Article

Immunoregulatory Potential of Mesenchymal Stem Cells following Activation by Macrophage-Derived Soluble Factors

Priming MSC with media conditioned by pro-inflammatory or anti-inflammatory macrophages enhanced their immunomodulatory potential through increased PGE2 secretion. Notably, the anti-inflammatory IL-10, mainly produced by pro-resolving macrophages, potentiated the priming effect of TNF-α. Collagen hydrogels acted as instructive microenvironments for MSC and macrophages functions and their crosstalk. [Stem Cell Res Ther] Full Article

Development and Characterization of Novel Clinical Grade Neonatal Porcine Bone Marrow-Derived Mesenchymal Stem Cells

The neonatal porcine bone marrow-derived MSCs (npBM-MSCs) expressed positive MSC markers CD29, CD44, and CD90 and were differentiated into chondrocytes, osteocytes, and adipocytes. The doubling time of npBM-MSCs was significantly shorter than that of human (h) BM-MSCs. The size of npBM-MSCs was also significantly smaller than that of hBM-MSCs. [Xenotransplantation] Abstract

IN VIVO

Cell-Cell Contact with Proinflammatory Macrophages Enhances the Immunotherapeutic Effect of Mesenchymal Stem Cells in Two Abortion Models

Immunosuppressive MSCs alleviated excessive inflammation by inhibiting CD4⁺ T cell proliferation and promoting the decidual macrophage switch to M2 in a tumor necrosis factor-stimulated gene-6 (TSG-6)-dependent manner. Cell-to-cell contact with proinflammatory macrophages increased the TSG-6 production by the MSCs, thereby enhancing the suppressive regulation of T cells and macrophages. [Cell Mol Immunol] Abstract

iPSC- and Mesenchymoangioblast-Derived Mesenchymal Stem Cells Provide Greater Protection against Experimental Chronic Allergic Airways Disease Compared with a Clinically Used Corticosteroid

Mesenchymoangioblast-derived MSCs (MCA-MSCs) were detected in the lungs up to five-seven days postadministration and demonstrated modest anti-inflammatory but striking antifibrotic effects against Ova-induced allergic airways disease, effectively decreasing airway hyperresponsiveness by 70-75%. Combining MCA-MSCs with dexamethasone provided equivalent protection to that offered by either therapy alone. [FASEB J] Abstract

Platelet-Rich Plasma Promotes the Regeneration of Cartilage Engineered by Mesenchymal Stem Cells and Collagen Hydrogel via the TGF-β/SMAD Signaling Pathway

The effect of platelet-rich plasma (PRP) on engineered cartilage constructed by MSCs and collagen hydrogel in vitro and in vivo was investigated and compared with TGF-β1. The results showed that PRP promoted cell proliferation and gene and protein expressions of chondrogenic markers via the TGF-β/SMAD signaling pathway. [J Cell Physiol] Abstract

Subscribe to one of our other 19 science newsletters such as ESC & iPSC News & Cell Therapy News.

Unveiling Mesenchymal Stromal Cells’ Organizing Function in Regeneration

The authors highlight the potential role of MSCs as regeneration organizers and speculate that this function emerges in cell sheets (CS). This concept shifts the understanding of the therapeutic mechanism underlying a widely known CS-based delivery method for regenerative medicine. [Int J Mol Sci] Full Article

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Longeveron Discusses Latest Stem Cell Findings for Aging Frailty

The company will discuss the positive results of its Phase I and Phase II trials examining the safety and efficacy of its stem cell treatments for Aging Frailty. [Press release from Longeveron LLC (PR Newswire Association LLC.) discussing research to be presented at the International Conference on Frailty & Sarcopenia Research, Miami] Press Release

Final Patient Dosed in Mesoblast Phase III Trial of Revascor Cell Therapy for Advanced Heart Failure

Mesoblast Limited announced that the last patient has now been dosed in the Phase III events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic heart failure. The 566-patient trial will complete when sufficient primary endpoint events have accrued, which is likely to be within 12 months. [Mesoblast Limited (GlobeNewswire, Inc.)] Press Release

Announcing the 2019 Sloan Research Fellows

The Alfred P. Sloan Foundation announced the selection of 126 outstanding US and Canadian researchers as the recipients of the 2019 Sloan Research Fellowships. The fellowships, awarded yearly since 1955, honor early-career scholars whose achievements mark them as among the most promising researchers in their fields. [The Alfred P. Sloan Foundation] Press Release

Nearly Half of US Female Scientists Leave Full-Time Science after First Child

More than 40% of women with full-time jobs in science leave the sector or go part time after having their first child, according to a study of how parenthood affects career trajectories in the United States. By contrast, only 23% of new fathers leave or cut their working hours. [Nature News] Editorial

Scientists Raise Concerns About Revisions to Human Research Regulations

Authors of a new paper take issue with revisions to regulations on biospecimen research enacted last month, and argue that cell lines should be treated differently from other biospecimens. [The Scientist] Editorial

Australia Dials Back Effort to Control ‘Dual Use’ Research

A review of Australian export laws has pushed back against the government’s effort to tighten controls on technologies and research that might have dual military and non-military uses. Australian researchers, who were concerned that sweeping controls would restrict collaborative research, have welcomed the findings. [Nature News] Editorial

NEW ISCT 2019 Annual Scientific Meeting
May 29-June 1, 2019
Melbourne, Australia

NEW Keystone Symposia: Cancer Stem Cells – Advances in Biology and Clinical Translation
October 13-17, 2019
Hong Kong, China

Visit our events page to see a complete list of events in the community.

NEW Tenure Track Professorship – Architectured Biomedical Materials for Tissue Regeneration (Charité Universitätsmedizin Berlin)

PhD Scholarship – Biomaterials Based Approach for Stem Cells Differentiation (Technical University of Denmark)

Research Scientist – Stem Cell Biology (MD Anderson Cancer Center)

Postdoctoral Fellow – MSC Research (University of Illinois at Chicago College of Medicine)

PhD Positions – Cancer Biology (Institut Curie)

Postdoctoral Training Fellow – Cancer Genomics (The Francis Crick Institute)

Assistant Professor – Sarcoma & Skeletal-Related Malignancies (UC Davis School of Medicine)

Postdoctoral Fellow – Stem Cell Biology (City of Hope)

Research Fellow – Stem Cell Biology (Brigham & Women’s Hospital – Harvard Medical School)

Post Doctoral Fellow – Stem Cell Biology (Technion – Israel Institute of Technology)

Assistant Professor – Department of Biological Sciences (Rutgers University Newark)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.